The Mumbai-based company, which is strong in various generic therapeutic segments, is eyeing biosimilars to fuel its future growth. The billionaire industrialist noted that for getting into vaccine production, a completely new set of manufacturing infrastructure is required. So, we currently don't have any facility which we are looking at for producing vaccines,” Mr Shanghvi said. On the biosimilar front, he noted that the drug firm is looking to develop a range of such products. On business outlook, Shanghvi noted: “Given the uncertainties of the pandemic in the near term, we are refraining from giving guidance for FY22.

Source: The Hindu June 13, 2021 11:15 UTC